Breaking Down SG&A Expenses: argenx SE vs Alkermes plc

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: argenx SE and Alkermes plc, from 2014 to 2023.

Key Insights

• argenx SE has shown a remarkable increase in SG&A expenses, growing from a modest $4.2 million in 2014 to a staggering $709 million in 2023. This represents an exponential growth, highlighting the company's aggressive expansion and investment in administrative capabilities.

• Alkermes plc, on the other hand, has maintained a more steady growth in expenses, starting at $200 million in 2014 and reaching $690 million by 2023. This consistent increase reflects a stable growth strategy.

Conclusion

The contrasting expense trajectories of these companies offer valuable insights into their strategic priorities and market positioning.